Chi­nese de­vel­op­ment group blue­prints $1B-plus biotech cam­pus in South San Fran­cis­co

When re­al es­tate bro­kers land­ed the 42-acre wa­ter­front site known as The Land­ing at Oys­ter Point in South San Fran­cis­co last fall, they oohed and aa­hed about its po­ten­tial as a new biotech cam­pus ly­ing ad­ja­cent to Genen­tech, one of the pi­o­neer­ing founders of the in­dus­try. It al­ready had a 443,000-square-foot busi­ness park in place, with po­ten­tial for hun­dreds of thou­sands of ad­di­tion­al space.

That all proved to be ir­re­sistible to a group of Chi­nese de­vel­op­ers who are now plan­ning to in­vest more than $1 bil­lion in­to the prop­er­ty, with ini­tial plans to add 500,000 square feet of of­fice and lab space for the re­gion’s boom­ing biotech in­dus­try. Tao­tao Song, CEO of Oys­ter Point De­vel­op­ment, LLC, and EVP at Green­land USA, a key play­er in the joint ven­ture de­vel­op­ment group, had this to say:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.